View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 02, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001124804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		177,952,607

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 135,003	$ 155,839
Restricted cash	8,769	6,659
Accounts receivable, net of allowance of $44,652 and $37,735 as of March 31, 2018 and December 31, 2017, respectively	495,695	567,873
Contract assets	45,068	0
Prepaid expenses and other current assets	130,051	115,463
Assets of disposal group held for sale	96,478	0
Total current assets	911,064	845,834
Fixed assets, net	164,878	165,603
Software development costs, net	235,845	222,189
Intangible assets, net	827,059	826,872
Goodwill	2,051,437	2,004,953
Deferred taxes, net	4,888	4,574
Contract assets - long-term	40,486	0
Other assets	129,610	148,849
Assets attributable to discontinued operations	4,945	11,276
Total assets	4,370,212	4,230,150
Current liabilities:
Accounts payable	101,818	97,583
Accrued expenses	102,028	85,915
Accrued compensation and benefits	82,141	99,632
Deferred revenue	540,289	546,830
Current maturities of long-term debt	19,503	27,687
Current maturities of non-recourse long-term debt - Netsmart	2,760	2,755
Current maturities of capital lease obligations	9,753	7,865
Liabilities of disposal group held for sale	31,048	0
Total current liabilities	889,340	868,267
Long-term debt	1,064,305	906,725
Non-recourse long-term debt - Netsmart	624,872	625,193
Long-term capital lease obligations	8,152	7,105
Deferred revenue	25,876	24,047
Deferred taxes, net	117,061	93,643
Other liabilities	72,526	92,205
Liabilities attributable to discontinued operations	14,276	21,358
Total liabilities	2,816,408	2,638,543
Redeemable convertible non-controlling interest - Netsmart	443,684	431,535
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of March 31, 2018 and December 31, 2017	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of March 31, 2018 and December 31, 2017; 270,601 and 177,953 shares issued and outstanding as of March 31, 2018, respectively; 269,335 and 180,832 shares issued and outstanding as of December 31, 2017, respectively	2,706	2,693
Treasury stock: at cost, 92,648 and 88,504 shares as of March 31, 2018 and December 31, 2017, respectively	380,335	322,735
Additional paid-in capital	1,770,801	1,781,059
Accumulated deficit	(319,271)	(338,150)
Accumulated other comprehensive loss	(2,181)	(1,985)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,071,720	1,120,882
Non-controlling interest	38,400	39,190
Total stockholders’ equity	1,110,120	1,160,072
Total liabilities and stockholders’ equity	$ 4,370,212	$ 4,230,150

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 44,652	$ 37,735
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	270,601,000	269,335,000
Common stock, shares outstanding	177,953,000	180,832,000
Treasury stock at cost, shares	92,648,000	88,504,000

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Software delivery, support and maintenance	$ 329,766	$ 268,188
Client services	184,160	145,287
Total revenue	513,926	413,475
Cost of revenue:
Software delivery, support and maintenance	104,410	83,397
Client services	154,768	124,939
Amortization of software development and acquisition-related assets	33,773	26,487
Total cost of revenue	292,951	234,823
Gross profit	220,975	178,652
Selling, general and administrative expenses	143,070	110,845
Research and development	69,977	49,232
Amortization of intangible and acquisition-related assets	12,248	7,312
(Loss) income from operations	(4,320)	11,263
Interest expense	(25,046)	(20,180)
Other (loss) income, net	(917)	239
Impairment of and losses on long-term investments	(5,500)	0
Equity in net (loss) income of unconsolidated investments	(61)	285
Loss from continuing operations before income taxes	(35,844)	(8,393)
Income tax benefit (provision)	2,914	(172)
Loss from continuing operations, net of tax	(32,930)	(8,565)
Income from discontinued operations, net of tax	4,415	0
Net loss	(28,515)	(8,565)
Less: Net loss (income) attributable to non-controlling interests	790	(453)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(12,149)	(10,962)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (39,874)	$ (19,980)
Basic
Continuing operations	$ (0.25)	$ (0.11)
Discontinued operations	0.03	0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	(0.22)	(0.11)
Diluted
Continuing operations	(0.25)	(0.11)
Discontinued operations	0.03	0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.22)	$ (0.11)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (28,515)	$ (8,565)
Other comprehensive income (loss):
Foreign currency translation adjustments	123	1,515
Change in unrealized gain (loss) on available for sale securities	0	(74,702)
Change in fair value of derivatives qualifying as cash flow hedges	(633)	1,348
Other comprehensive loss before income tax benefit (expense)	(510)	(71,839)
Income tax benefit (expense) related to items in other comprehensive loss	314	(521)
Total other comprehensive loss	(196)	(72,360)
Comprehensive loss	(28,711)	(80,925)
Less: Comprehensive loss (income) attributable to non-controlling interests	790	(453)
Comprehensive loss, net	$ (27,921)	$ (81,378)

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net (loss) income	$ (28,515)	$ (8,565)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	65,912	49,694
Stock-based compensation expense	11,952	7,946
Deferred taxes	(5,048)	(1,570)
Impairment of and losses on long-term investments	5,500	0
Equity in net loss (income) of unconsolidated investments	61	(285)
Other losses, net	50	1,240
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	34,780	(8,010)
Prepaid expenses and other assets	(4,259)	(4,464)
Accounts payable	4,122	2,869
Accrued expenses	13,259	(5,567)
Accrued compensation and benefits	(21,074)	(5,501)
Deferred revenue	(21,319)	48,687
Other liabilities	2,887	(997)
Net cash provided by operating activities	58,308	75,477
Cash flows from investing activities:
Capital expenditures	(8,602)	(14,524)
Capitalized software	(32,227)	(34,011)
Cash paid for business acquisitions, net of cash acquired	(109,020)	(3,975)
Other proceeds from investing activities	37	0
Net cash used in investing activities	(149,812)	(52,510)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	212	0
Taxes paid related to net share settlement of equity awards	(8,496)	(5,864)
Payments of capital lease obligations	(2,804)	(3,015)
Credit facility payments	(1,217)	(86,726)
Credit facility borrowings, net of issuance costs	145,843	80,000
Repurchase of common stock	(57,599)	0
Payment of acquisition financing obligations	(3,226)	0
Net cash provided by (used in) financing activities	72,713	(15,605)
Effect of exchange rate changes on cash and cash equivalents	65	419
Net (decrease) increase in cash and cash equivalents	(18,726)	7,781
Cash, cash equivalents and restricted cash, beginning of period	162,498	96,610
Cash, cash equivalents and restricted cash, end of period	$ 143,772	$ 104,391

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2018 and 2017 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the full year ending December 31, 2018. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Change in Presentation During the first quarter of 2018, we changed the presentation of certain bundled revenue streams. Such revenue was previously included as part of software delivery, support and maintenance revenue. Under the new presentation, such revenue is included as part of client services revenue. The revenue previously reported for the first quarter of 2017 has been recast to match the new presentation by reducing software delivery, support and maintenance and increasing client services by $4.3 million. Significant Accounting Policies We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) effective on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. There have been no other changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The amendments in ASU 2016-01 modify the requirements related to the measurement of certain financial instruments in the statement of financial condition and results of operation. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee), are required to be measured at fair value with changes in fair value recognized in net income. An entity may continue to elect to measure equity investments which do not have a readily determinable fair value at cost with adjustments for impairment, if any, and observable changes in price. In addition, for a liability (other than a derivative liability) that an entity measures at fair value, any change in fair value related to the instrument-specific credit risk, (i.e., the entity’s own credit risk), should be presented separately in other comprehensive income and not as a component of net income. ASU 2016-01 also clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for interim and annual periods beginning after December 15, 2017 with early adoption permitted solely for the instrument-instrument specific credit risk for liabilities measured at fair value. The amendments should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption. We adopted ASU 2016-01 effective January 1, 2018 and there was no immediate impact upon adoption. Refer to Note 3, “Fair Value Measurements”, for additional information regarding our unconsolidated equity investments. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). ASU 2017-01 provides new accounting guidance to assist an entity in evaluating when a set of transferred assets and activities is a business. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, and should be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We adopted ASU 2017-01 effective January 1, 2018 and there was no immediate impact upon adoption. Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) intended to improve financial reporting about leasing transactions. The new guidance will require entities that lease assets to recognize on their balance sheets the assets and liabilities for the rights and obligations created by those leases and to disclose key information about the leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. We are currently evaluating the impact of this accounting guidance, including the timing of adoption. In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which provides new accounting guidance to simplify the accounting for goodwill impairment. ASU 2017-04 removes Step Two of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the new guidance, a goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill assigned to the reporting unit. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. ASU 2017-04 is effective for annual and interim periods in fiscal years beginning after December 15, 2019 with early adoption permitted for any goodwill impairment tests performed after January 1, 2017. The new guidance is to be applied prospectively. We are currently evaluating the impact of this accounting guidance, including the timing of adoption. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”), which provides new accounting guidance to simplify and improve the reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in this Update make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted in any interim period after the issuance of this Update. We are currently evaluating the impact of this accounting guidance, including the timing of adoption. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations

3 Months Ended

Mar. 31, 2018

Business Combinations [Abstract]

Business Combinations

2. Business Combinations

2018 Business Combinations

Acquisition of Practice Fusion, Inc.

On February 13. 2018, we completed the acquisition of Practice Fusion, Inc., a Delaware corporation (“Practice Fusion”), for aggregate consideration of $113.7 million paid in cash. Practice Fusion offers an affordable certified cloud-based electronic health record (“EHR”) for traditionally hard-to-reach small, independent physician practices. The consideration paid for Practice Fusion is shown below:

	(In thousands)
Aggregate purchase price	$	100,000
Add: Net working capital surplus		469
Less: Adjustment for assumed indebtedness		(1,684	)
Add: Closing cash		14,951
Total consideration paid for Practice Fusion	$	113,736

The allocation of the fair value of the consideration transferred as of the acquisition date of February 13, 2018 is shown in the table below. This allocation is preliminary and subject to changes, which could be significant, as appraisals of tangible and intangible assets are finalized, and additional information becomes available. The goodwill is not expected to be deductible for tax purposes.

	(In thousands)
Cash and cash equivalents	$	14,951
Accounts receivable, net		13,397
Prepaid expenses and other current assets		809
Fixed assets		1,764
Intangible assets		67,200
Goodwill		34,739
Other assets		43
Accounts payable and accrued expenses		(7,620	)
Deferred revenue		(2,400	)
Long-term deferred tax liability		(8,332	)
Other liabilities		(815	)
Net assets acquired	$	113,736

The following table summarizes the preliminary fair values of the identifiable intangible assets and their estimated useful lives:

	Useful Life	Fair Value
Description	(In years)	(In thousands)
Customer Relationships - Physician Practices	15	$	28,700
Customer Relationships - Pharmaceutical Partners	20		19,800
Technology	8		14,800
Tradenames	10		3,900
		$	67,200

We incurred $0.5 million of acquisition costs which are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the quarter ended March 31, 2018. The results of operations of Practice Fusion were not material to our consolidated results of operations for the quarter ended March 31, 2018.

Other Acquisitions and Divestiture

On February 6, 2018 the Company acquired all of the common stock of a cloud-based analytics software platform provider for a purchase price of $8.0 million in cash. The allocation of the consideration is as follows: $3.7 million of intangible assets related to technology; $0.6 million to customer relationships; $4.8 million of goodwill; $0.8 million to accounts receivable; accounts payable of $0.2 million; deferred revenue of $0.6 million and $1.1 million of long-term deferred income tax liabilities. This allocation is preliminary and subject to changes, which could be significant, as appraisals of tangible and intangible assets are finalized, and additional information becomes available. The acquired intangible asset related to the technology will be amortized over 8 years using a method that approximates the pattern of economic benefits to be gained by the intangible asset. The customer relationship will be amortized over one year. The goodwill is not deductible for tax purposes. The results of operations of this acquisition were not material to our consolidated results of operations for the three months ended March 31, 2018.

On January 31, 2018, Netsmart (as defined below) entered into a Unit Purchase Agreement with a third party provider of billing solutions, for aggregate consideration of $5.4 million, plus net working capital consideration relative to a predetermined target, to acquire 100% of the equity of the entity. This transaction has been accounted for as a business combination. Of the total consideration, $2.0 million was paid in cash at closing with the remaining $3.6 million to be paid evenly on the first and second anniversaries of closing. This transaction resulted in the preliminary recognition of goodwill of $1.4 million. The purchase accounting for this transaction has not yet been completed. The results of operations of this acquisition were not material to our consolidated results of operations for the three months ended March 31, 2018.

On March 15, 2018, we entered into an agreement with a third party to contribute certain assets and liabilities of our strategic sourcing business unit, acquired as part of the acquisition of the EIS Business in 2017 discussed below, into a new entity. We were also obligated to contribute $2.7 million of cash as additional consideration, which was paid during April 2018. In exchange for our contributions, we obtained a 35.7% interest in the new entity, which was valued at $4.0 million and is included in Other assets in our consolidated balance sheet as of March 31, 2018. This investment will be accounted for under the equity method of accounting. As a result of this transaction, we recognized a loss of $0.9 million, which is included on the “Other (loss)/income, net” line in our consolidated statement of operations for the three months ended March 31, 2018.

Pre-2018 Business Combination Updates

Acquisition of DeVero

On July 17, 2017, Netsmart completed the acquisition of DeVero, Inc. (“DeVero”), a healthcare technology company that develops electronic medical record solutions for home healthcare and hospice, for an aggregate purchase price of $50.5 million in cash. At March 31, 2018 the allocation of the purchase price is final and there were no measurement period adjustments recorded during the three months ended March 31, 2018.

Acquisition of the Patient/Provider Engagement Solutions Business from NantHealth, Inc.

On August 25, 2017, the Company completed the acquisition of substantially all of the assets relating to the provider/patient engagement solutions business of NantHealth, Inc. (“NantHealth”). During the three months ended March 31, 2018, measurement period adjustments to the purchase price allocation were recorded which resulted in an increase in goodwill of $0.1 million. At March 31, 2018 the purchase price allocation remains subject to further adjustment, primarily with respect to net working capital acquired.

Acquisition of the Enterprise Information Solutions Business from McKesson Corporation

On October 2, 2017, Allscripts Healthcare, LLC, a wholly-owned subsidiary of the Company (“Healthcare LLC”), completed the acquisition of McKesson Corporation’s Enterprise Information Solutions Business division (the “EIS Business”), which provides certain software solutions and services to hospitals and health systems, by acquiring all of the outstanding equity interests of two indirect, wholly-owned subsidiaries of McKesson Corporation. The acquisition of the EIS Business was based on a total enterprise value of $185 million. During the three months ended March 31, 2018, measurement period adjustments to the purchase price allocation were recorded which resulted in an increase in goodwill of $37.7 million, primarily resulting from an increase in deferred revenue of $44.0 million partially offset by increases in identified intangible assets of $6.6 million. At March 31, 2018 the purchase price allocation remains subject to further adjustment, primarily with respect to certain acquired intangible assets and deferred revenue.

Formation of Joint Business Entity and Acquisition of Netsmart, Inc.

On March 20, 2016, we entered into a Contribution and Investment Agreement with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI Partners”), to form a joint business entity to which we contributed our Homecare^TM business and GI Partners made a cash contribution. On April 19, 2016, the joint business entity acquired Netsmart, Inc., a Delaware corporation. As a result of these transactions (the “Netsmart Transaction”), the joint business entity combined the Allscripts Homecare^TM business with Netsmart, Inc. Throughout the rest of this Form 10-Q, the joint business entity is referred to as “Netsmart”. As part of the Netsmart Transaction, we deposited $15 million in an escrow account to be used by Netsmart to facilitate the integration of our Homecare^TM business within Netsmart over the next five years, at which time the restriction on any unused funds will lapse. As of March 31, 2018, there is $9.0 million remaining in the escrow account. We finalized the allocation of the fair value of the consideration transferred as of December 31, 2016.

Supplemental Information

The supplemental pro forma results below were calculated after applying our accounting policies and adjusting the results of the EIS Business and NantHealth to reflect (i) the additional amortization that would have been charged resulting from the fair value adjustments to intangible assets (ii) the additional interest expense associated with Allscripts’ borrowings under its revolving facility, and (iii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value that would have been charged assuming both acquisitions occurred on January 1, 2016, together with the consequential tax effects.

The revenue and earnings of the EIS Business, since October 2, 2017, and NantHealth, since August 25, 2017, are included in our consolidated statement of operations for the three months ended March 31, 2018. The below supplemental pro forma revenue and net loss of the combined entity is presented as if both acquisitions had occurred on January 1, 2016.

(In thousands, except per share amounts)	Three Months Ended March 31, 2017
Supplemental pro forma data for combined entity:
Revenue	$	520,810
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(17,572	)
Loss per share, basic and diluted	$	(0.10	)

Fair Value Measurements and Long-term Investments

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements and Long-term Investments

3. Fair Value Measurements and Long-term Investments

Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories:

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. We held no Level 1 financial instruments at March 31, 2018 or December 31, 2017.

Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments.

Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. The sensitivity of changes in the unobservable inputs to the valuation pricing model used to value these instruments is not material to our consolidated results of operations.

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:

	Balance Sheet	March 31, 2018										December 31, 2017
(In thousands)	Classifications	Level 1		Level 2		Level 3			Total			Level 1		Level 2		Level 3			Total
1.25% Call Option	Other assets	$	0	$	0	$	25,410		$	25,410		$	0	$	0	$	46,578		$	46,578
1.25% Embedded cash conversion option	Other liabilities		0		0		(26,446	)		(26,446	)		0		0		(47,777	)		(47,777	)
Foreign exchange derivative assets	Prepaid expenses and other current assets		0		503		0			503			0		1,136		0			1,136
Total		$	0	$	503	$	(1,036	)	$	(533	)	$	0	$	1,136	$	(1,199	)	$	(63	)

Long-term Investments

The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets:

	Number of
	Investees		Original		Carrying Value at
(In thousands, except # of investees)	at March 31, 2018		Investment		March 31, 2018		December 31, 2017
Equity method investments ⁽¹⁾		4	$	5,658	$	7,197	$	3,258
Cost method investments		7		32,784		21,820		26,755
Total equity investments		11	$	38,442	$	29,017	$	30,013

_________________________________

⁽¹⁾

Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

As of March 31, 2018, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital, and observable price changes in orderly transactions.

Impairment of Long-term Investments

Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. As a result of this review, we recognized a non-cash impairment charge of $5.5 million related to one of our cost-method equity investments and a related note receivable, which had cost bases of $4.9 million and $2.6 million, respectively, prior to the impairment.

Long-term Financial Liabilities

Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as March 31, 2018, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Shareholders' Equity

4. Stockholders' Equity

Stock-based Compensation Expense

Stock-based compensation expense recognized during the three months ended March 31, 2018 and 2017 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. In addition, the three-month periods ended March 31, 2018 and 2017 include stock-based compensation expense related to Netsmart’s time-based liability classified option awards. No stock-based compensation costs were capitalized during the three months ended March 31, 2018 and 2017.

	Three Months Ended March 31,
(In thousands)	2018		2017
Cost of revenue:
Software delivery, support and maintenance	$	616	$	1,125
Client services		1,436		1,572
Total cost of revenue		2,052		2,697
Selling, general and administrative expenses		7,245		3,550
Research and development		2,841		2,589
Total stock-based compensation expense	$	12,138	$	8,836

Allscripts Long-Term Incentive Plan

We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.

The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three months ended March 31, 2018 and 2017.

We granted stock-based awards as follows:

	Three Months Ended March 31, 2018
			Weighted-Average
			Grant Date
(In thousands, except per share amounts)	Shares		Fair Value
Service-based restricted stock units		1,300	$	14.20
Performance-based restricted stock units with a service condition		524	$	15.74
Market-based restricted stock units with a service condition		0	$	0.00
		1,824	$	14.64

During the three months ended March 31, 2018, and the year ended December 31, 2017, 1.3 million and 1.3 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards.

Net Share-settlements

Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the three months ended March 31, 2018 and 2017 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2018 and 2017 were 609 thousand and 494 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.

Stock Repurchases

On November 17, 2016, we announced that our Board approved a stock purchase program under which we may repurchase up to $200 million of our common stock through December 31, 2019. During the three months ended March 31, 2018, we repurchased 4.1 million shares of our common stock under the program for a total of $57.6 million. There were no repurchases under the program during the three months ended March 31, 2017. The approximate dollar value of shares that may yet be purchased under the program as of March 31, 2018 was $106.4 million. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Netsmart Stock-based Compensation Expense

Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards totaled $1.2 million and ($3.5) million during the three months ended March 31, 2018 and 2017, respectively.

At March 31, 2018, the liability for outstanding awards was $9.2 million. As of March 31, 2018 the weighted average fair value per option unit using the Black‑Scholes‑Merton option pricing model was estimated at $0.30, as compared to $0.54 at December 31, 2016. A significant portion of the decrease in fair value occurred during the first quarter of 2017 and resulted in the reversal of previously recognized stock-based compensation expense during the three months ended March 31, 2017, as required under the liability method of accounting.

During the three months ended March 31, 2018, no option unit awards were granted by Netsmart .

Earnings (Loss) Per Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

5. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.

The calculations of earnings (loss) per share are as follows:

	Three Months Ended March 31,
(In thousands, except per share amounts)	2018			2017
Basic Loss per Common Share:
(Loss) income from continuing operations, net of tax	$	(32,930	)	$	(8,565	)
Less: Net loss (income) attributable to non-controlling interests		790			(453	)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart		(12,149	)		(10,962	)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(44,289	)	$	(19,980	)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		4,415			0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(39,874	)	$	(19,980	)

Weighted-average common shares outstanding		179,882			180,767

Basic Loss from continuing operations per Common Share	$	(0.25	)	$	(0.11	)
Basic Income from discontinued operations per Common Share		0.03			0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.22	)	$	(0.11	)

Diluted Loss per Common Share:
(Loss) income from continuing operations, net of tax	$	(32,930	)	$	(8,565	)
Less: Net loss (income) attributable to non-controlling interests		790			(453	)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart		(12,149	)		(10,962	)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(44,289	)	$	(19,980	)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		4,415			0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(39,874	)	$	(19,980	)

Weighted-average common shares outstanding		179,882			180,767
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants		0			0
Weighted-average common shares outstanding assuming dilution		179,882			180,767

Diluted Loss from continuing operations per Common Share	$	(0.25	)	$	(0.11	)
Diluted Income from discontinued operations per Common Share		0.03			0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.22	)	$	(0.11	)

As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three months ended March 31, 2018 and 2017, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive.

The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:

Three Months Ended

March 31,

(In thousands)

2018

2017

Shares subject to anti-dilutive stock options, restricted stock

unit awards and warrants excluded from calculation

23,208

26,689

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

6. Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:

	March 31, 2018							December 31, 2017
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	693,844	$	(419,081	)	$	274,763	$	695,354	$	(405,114	)	$	290,240
Customer contracts and relationships		948,703		(475,407	)		473,296		922,492		(464,860	)		457,632
Total	$	1,642,547	$	(894,488	)	$	748,059	$	1,617,846	$	(869,974	)	$	747,872

Intangibles not subject to amortization:
Registered trademarks						$	79,000						$	79,000
Goodwill							2,051,437							2,004,953
Total						$	2,130,437						$	2,083,953

Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2018 were as follows:

	Clinical and			Population
(In thousands)	Financial Solutions			Health			Netsmart		Total
Balance as of December 31, 2017	$	861,615		$	431,132		$	712,206	$	2,004,953
Additions arising from business acquisitions:
Practice Fusion acquisition		34,739			0			0		34,739
Other acquisitions		4,829			0			1,374		6,203
Total arising from business acquisitions		39,568			0			1,374		40,942
Increases (decreases) due to measurement period adjustments:
NantHealth provider/patient solutions business		0			117			0		117
Enterprise Information Solutions business		9,204			28,454			0		37,658
Other measurement period adjustments		(205	)		0			0		(205	)
Total increases (decreases) due to measurement period adjustments:		8,999			28,571			0		37,570
Total additions to goodwill		48,567			28,571			1,374		78,512
Divestitures		(30,105	)		(2,198	)		0		(32,303	)
Foreign exchange translation		275			0			0		275
Balance as of March 31, 2018	$	880,352		$	457,505		$	713,580		2,051,437

There were no accumulated impairment losses associated with our goodwill as of March 31, 2018 or December 31, 2017.

Additions during the first quarter of 2018 include goodwill of $34.7 million arising from Allscripts’ purchase of Practice Fusion, Inc. Other additions during the first quarter of 2018 include $4.8 million arising from Allscripts’ purchase of a third party cloud-based analytics software platform provider, and $1.4 million arising from Netsmart’s acquisition of a third party provider of billing solutions. Measurement period adjustments include $37.7 million related to the 2017 purchase of the EIS Business. Goodwill was reduced by $2.2 million due to the divestiture of our strategic sourcing business unit, and by $30.1 million related to the OneContent business, which is classified as held for sale at March 31, 2018. Refer to Note 2, “Business Combinations,” for additional information regarding these transactions.

Effective January 1, 2018, we made organizational changes that affected the Clinical and Financial Solutions, and Population Health reportable segments. Refer to Note 14, “Business Segments” for additional information. As a result of these changes, the dbMotion business unit, formerly included in the Population Health operating segment within the Population Health reportable segments, is now aligned with the Hospitals and Health Systems operating segment within the Clinical and Financial solutions reportable segment.

We performed our annual goodwill impairment test as of October 1, 2017, our annual testing date, and again as of January 1, 2018 in connection with the organizational changes referred to above. While there was no impairment indicated as a result of the January 1, 2018 test, the estimated fair value of our Hospitals and Health Systems reporting unit exceeded the unit’s carrying value by 10%. As of March 31, 2018, the goodwill allocated to the Hospitals and Health Systems reporting unit was $511.2 million. The determination of the fair value of our reporting units is based on a combination of a market approach, that considers benchmark company market multiples, and an income approach, that utilizes discounted cash flows for each reporting unit and other Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent cash flow projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations of future performance and the expected future economic environment, which are partly based upon our historical experience. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in assessing the reasonableness of the combined fair values estimated for our reporting units. Because the fair value of the Hospitals and Health Systems reporting unit was not substantially in excess of its carrying value at January 1, 2018, there is an increased risk that any adverse trends in the foregoing assumptions with respect to the Hospitals and Health Systems reporting unit could cause the estimated fair value to fall below the carrying value, which would result in an impairment of the reporting unit’s goodwill.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Revenue from Contracts with Customers

3 Months Ended

Mar. 31, 2018

Revenue From Contract With Customer [Abstract]

Revenue from Contracts with Customers

7. Revenue from Contracts with Customers

Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery revenue consists of all of our proprietary software sales (either as a perpetual or term license delivery model), transaction-related revenue and the resale of hardware and third-party software. Support and maintenance revenue consists of revenue from post contract client support and maintenance services, which includes telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services or project-based revenue from implementation, training and consulting services. In addition, for some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees.

Adoption of New Revenue Standard

In May 2014, the FASB issued ASC 606 to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASC 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASC 606 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under the previous ASC 605, Revenue Recognition (“ASC 605”), including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. Additionally, ASC 606 provides guidance related to costs of obtaining a contract with a customer that an entity expects to recover.

The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We have adopted the standard effective on January 1, 2018 using the modified retrospective method. We also implemented internal controls and updated our processes and key systems to allow us to comply with the new requirements.

The reported results for the three months ended March 31, 2018 reflect the adoption of ASC 606. The comparative information for the three months ended March 31, 2017 has not been restated and will continue to be reported under the previous guidance of ASC 605, which was in effect during that period. The following adjustments were made to balances previously reported on the condensed consolidated balance sheet as of December 31, 2017:

	As Reported			Adjustments			Adjusted
(In thousands, except per share amounts)	December 31, 2017			due to ASC 606			January 1, 2018
Accounts receivable, net	$	567,873		$	(32,529	)	$	535,344
Contract assets		0			76,509			76,509
Prepaid expenses and other current assets		115,463			11,646			127,109

Deferred revenue, current		546,830			(7,453	)		539,377
Deferred revenue, long-term		24,047			0			24,047
Deferred taxes, net		93,643			16,478			110,121
Accumulated deficit		(338,150	)		46,601			(291,549	)

The adoption of ASC 606 had no impact on cash from or used in operating, financing or investing activities reported in our consolidated statement of cash flows for the year ended December 31, 2017. The following tables compare the reported consolidated balance sheet and statement of operations as of and for the three months ended March 31, 2018, to the pro-forma amounts assuming the previous guidance of ASC 605 had been in effect:

	March 31, 2018
(In thousands, except per share amounts)	As reported under ASC 606			Adjustments due to ASC 606			Pro forma under ASC 605
Accounts receivable, net	$	495,695		$	78,302		$	573,997
Contract assets		45,068			(45,068	)		0
Prepaid expenses and other current assets		130,051			33			130,084
Contract assets - long-term		40,486			(40,486	)		0

Deferred revenue, current		540,289			(972	)		539,317
Deferred taxes, net		117,061			(1,629	)		115,432
Accumulated deficit		(319,271	)		(4,618	)		(323,889	)

	Three Months Ended March 31, 2018
(In thousands, except per share amounts)	As reported under ASC 606			Adjustments due to ASC 606			Pro forma under ASC 605
Software delivery, support and maintenance	$	329,766		$	(5,028	)	$	324,738
Client services		184,160			(1,066	)		183,094
Gross profit		220,975			(6,279	)		214,696
Selling, general and administrative expenses		143,070			(218	)		142,852
Loss from operations		(4,320	)		(6,061	)		(10,381	)
Loss from continuing operations before income taxes		(35,844	)		(6,247	)		(42,091	)
Income tax benefit		2,914			1,629			4,543
Net loss		(28,515	)		(4,618	)		(33,133	)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(39,874	)		(4,618	)	$	(44,492	)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(0.22	)		(0.03	)	$	(0.25	)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(0.22	)		(0.03	)	$	(0.25	)

The recognition of revenue related to hardware sales, software-as-a-service-based offerings, client services, electronic data interchange services, and managed services remained substantially unchanged under ASC 606. The adoption of ASC 606 resulted in an increase in contract assets driven by upfront recognition of revenue, rather than over the subscription period, from certain multi-year software subscription contracts that include both software licenses and software support and maintenance.

Costs to Obtain or Fulfill a Contract

Under ASC 605, we only capitalized direct sales commissions that were specifically associated with new or renewal contracts. The new revenue recognition guidance under ASC 606 requires the capitalization of all incremental costs of obtaining a contract with a customer that an entity expects to recover. As part of our implementation efforts, we identified certain indirect commissions and other payments that would be eligible for capitalization under ASC 606 as they are incremental costs solely associated with new or renewal contracts that we expect to recover. Certain costs related to the fulfillment of contracts will also be capitalized. As a result, we recorded a deferral for such costs of $8.6 million, net of tax, upon adoption of the new guidance on January 1, 2018, which was included in the cumulative effect of initially applying ASC 606.

Capitalized costs to obtain or fulfill a contract are amortized over periods ranging from two to nine years which represent the contract term or a longer period, if renewals are expected and the renewal commission, if any, is not commensurate with the initial commission. We classify such capitalized costs as current or non-current based on the expected timing of expense recognition. The current and non-current portion are included in prepaid expenses and other current assets, and other assets, respectively, in our consolidated balance sheets.

At March 31, 2018, we had $27.4 million of capitalized costs to obtain or fulfill a contract. During the three months ended March 31, 2018, we recognized $8.2 million of amortization expense related to such capitalized costs, of which $8.1 million is included in selling, general and administrative expenses and $0.1 million is included in cost of revenue, in our consolidated statements of operations.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivables, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue.

In general, with the exception of fixed fee project-based client service offerings (such as implementation services), we sell our software solutions on date-based milestone events where control transfers and use of the software occurs on the delivery date but the associated payments for the software license occur on future milestone dates. In such instances, unbilled amounts are included in contract assets since our right to receive payment is conditional upon the continued functionality of the software and the provision of ongoing support and maintenance. Our fixed fee project-based client service offerings typically require us to provide the services with either a significant portion or all amounts due prior to service completion. Since our right to payment is not unconditional, amounts associated with work prior to the completion date are also deemed to be contract assets.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account in ASC 606. A performance obligation is considered distinct when both (i) a customer can benefit from the product or service either on its own or together with other resources that are readily available to the customer and (ii) the promised product or service is separately identifiable from other promises in the contract. Activities related to the fulfillment of a contract that do not transfer products or services to a customer, such as contract preparation or legal review of contract terms, are not deemed to be performance obligations. Based on the similarities in the definitions of a “deliverable” under ASC 605 and “performance obligation” under ASC 606, our identification of performance obligations did not result in a significant divergence from our existing identification approach.

We generally sell our solutions through multi-element arrangements where we provide the customer with (1) software license, (2) support and maintenance, (3) embedded content such as third-party software and (4) client services. Incremental solutions, such as hardware and managed services are also provided based upon a customer’s preferences and requirements. We deem that a customer is typically able to benefit from a product or service on its own or together with readily available resources when we sell such product or service on a standalone basis. We have historically sold the majority of our performance obligations with the exception of software licenses, on a standalone basis. Incremental solutions, such as hardware, client services and managed services, are often negotiated and fulfilled on an independent sales order basis as customer needs and requirements grow over the course of a relationship period. In addition, support and maintenance and embedded content are provided on a stand-alone basis through the renewal process.

One of the product offerings under our CareInMotion^TM platform requires a significant client service customization to enable the functionality of the software before the customer can obtain benefit from using the product. The significant customization cannot be performed by a third party. Software products and client services are separately identifiable in these contracts, but the performance obligations are not considered distinct in the context of the contract. Therefore, these products and services are treated as combined performance obligations.

Additionally, our support and maintenance obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance obligations within our overall support and maintenance obligations can be viewed as a single performance obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently.

Generally, we do not provide additional warranties to clients above and beyond warranties that the solutions purchased will perform in accordance with the agreed-upon specifications. On rare occasions, when additional warranties are granted, we evaluate on a case-by-case basis whether the additional warranty represents a separate performance obligation.

The breakdown of revenue recognized related to various performance obligations and elected accounting expedients is presented in the table below:


(In thousands)	Three Months Ended March 31, 2018
Revenue related to deferred revenue balance at beginning of period	$	204,297
Revenue related to new performance obligations satisfied during the period		257,222
Revenue recognized under "right-to-invoice" expedient		49,638
Reimbursed travel expenses, shipping and other revenue		2,769
Total revenue	$	513,926

The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”) represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled $4.7 billion as of March 31, 2018, of which we expect to recognize approximately 36% over the next 12 months, and the remaining 64% thereafter.

Accounting Policy Elections and Practical Expedients

The majority of our contracts contain provisions that require customer payment no later than one year from the transfer of control of the related performance obligation. Perpetual software license contracts in which payments range from 2 to 10 years contain a financing component. Interest income is recognized in these circumstances and totaled $0.2 million during the three months ended March 31, 2018.

We have elected to exclude from the measurement of the transaction price all taxes (e.g. sales, use, value-added, etc.) assessed by government authorities and collected from a customer. Therefore, revenue is recognized net of such taxes.

Within the normal course of business, we contract with customers to deliver and ship tangible products such as computer hardware or licensed software disks. In these situations, the control of the products transfers to the customer when the product reaches the shipper based on free on board (FOB) shipping clauses. We have elected to use the practical expedient allowed under ASC 606 to account for shipping and handling activities that occur after the customer has obtained control of a promised good as fulfillment costs rather than as an additional promised service and, therefore, we do not allocate a portion of the transaction price to a shipping service obligation. Instead, we record as revenue any amounts billed to customers for shipping and handling costs and record as cost of revenue the actual shipping costs incurred.

Additionally, our standard contract terms allow for the reimbursement by the customer for certain travel expenses necessary to provide on-site services to customer, such as implementation and training. Such reimbursed travel expenses are reported on a gross basis. Since such reimbursed travel expenses do not represent a distinct good or service nor represent incremental value provided to the customer, a performance obligation is deemed not to exist. In certain situations, however, when the allowable reimbursable expenses amount is capped, we believe that such cap represents the most likely amount of variable consideration and the capped amount is included in the total contract transaction price.

In accordance with ASC 606, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice (“right-to-invoice” practical expedient). We have elected to utilize this expedient as it relates to transaction-based services (such as revenue cycle management) and electronic data interchange transactions.

Revenue Recognition

We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer.

The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware where we determined that a customer obtains control of the asset upon delivery, shipment or granting of access. The following table summarizes the pattern of revenue recognition for our most significant performance obligations:

Performance Obligation	Revenue Recognition Pattern	Measure of progress
Support and maintenance (SMA)	Over time	Output method (time elapsed) – revenue is recognized ratably over the contract term
Software as a service (SaaS)	Over time	Output method (time elapsed) – revenue is recognized ratably over the contract term
Private Cloud Hosting	Over time	Output method (time elapsed) – revenue is recognized ratably over the contract term
Client/Education Services	Over time	Input method (cost to cost) – revenue is recognized proportionally over the service implementation based on hours
Outsourcing services	Over time	Input method (cost to cost) – revenue is recognized proportionally over the outsourcing period
Payerpath (transaction volume)	Over time	Output method ("right-to-invoice" practical expedient) – value transferred to the customer is reflected on invoicing.
Software Licenses	Point in time	Upon shipment or electronically delivered, as applicable
Hardware	Point in time	Upon shipment

When evaluating our SMA, SaaS and private cloud hosting performance obligations, we noted that these obligations are fulfilled as stand-ready obligations to perform and, therefore, we deem the obligations to be satisfied evenly over time. Client services, such as those relating to implementation, consulting, training or education, are generally not fulfilled evenly over the contract period but rather over a shorter timeline where work effort can rise, or decline based upon stages of the project work effort. These client services are typically quoted to a customer as a fixed fee amount that covers the implementation effort. Delivery progress for these services is measured by establishing an approved cost budget with labor hour inputs utilized to gauge percentage of completion of the work effort. Therefore, revenue for our client, education and outsourcing services is recognized proportionally with the progress of the implementation work effort.

Payerpath transaction volume and other transaction-based service obligations, such as revenue cycle management services, are fulfilled over time but are not provided evenly over the contract period and reliable inputs are not available to track progress of completion. We determined that value is provided to the customer throughout the contract period and the pricing charged to the customer varies on a monthly basis, based upon the volume of the customer’s transactions processed in that respective period. The invoiced amount to the customer represents this value and accordingly the practical expedient to recognize revenue based upon invoicing is most appropriate.

We considered the specific implementation guidance for accounting for licenses of intellectual property (“IP”) to determine if point in time or over time recognition was more appropriate. The first step in the licensing framework is to determine whether the license is distinct or combined with other goods and services. For most of our software licensing products, the licenses are distinct, with the exception of one of our product offerings under our CareInMotion^TM platform, which requires a significant client service customization. In all instances, we determined that we are offering functional IP as compared with a symbolic IP. Functional IP is a right to use IP because the IP has standalone functionality and the customer can use the IP as it exists at a point in time.

Disaggregation of Revenue

We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments:

	Three Months Ended March 31,
(In thousands)	2018		2017
Revenue:
Software delivery, support and maintenance
Recurring revenue	$	294,455	$	227,450
Non-recurring revenue		35,311		40,738
Total software delivery, support and maintenance		329,766		268,188
Client services
Recurring revenue	$	122,474	$	101,779
Non-recurring revenue		61,686		43,508
Total client services		184,160		145,287
Total revenue	$	513,926	$	413,475

	Three Months Ended March 31, 2018
(In thousands)	Clinical and Financial Solutions		Population Health		Netsmart		Unallocated			Discontinued Operations			Total
Software delivery, support and maintenance	$	230,557	$	61,198	$	49,245	$	1,165		$	(12,399	)	$	329,766
Client services		143,422		8,507		33,241		(3,113	)		2,103			184,160
Total revenue	$	373,979	$	69,705	$	82,486	$	(1,948	)	$	(10,296	)	$	513,926



	Three Months Ended March 31, 2017
(In thousands)	Clinical and Financial Solutions		Population Health		Netsmart		Unallocated			Discontinued Operations			Total
Software delivery, support and maintenance	$	178,330	$	39,689	$	46,496	$	3,673		$	0		$	268,188
Client services		117,850		3,741		26,511		(2,815	)		0			145,287
Total revenue	$	296,180	$	43,430	$	73,007	$	858		$	0		$	413,475

Debt

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Debt

8. Debt

Debt outstanding, excluding capital leases, consists of the following:

	March 31, 2018						December 31, 2017
(In thousands)	Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount		Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount
1.25% Cash Convertible Senior Notes	$	345,000	$	32,571	$	312,429	$	345,000	$	35,978	$	309,022
Senior Secured Credit Facility		778,750		7,371		771,379		628,750		3,360		625,390
Netsmart Non-Recourse Debt:
First Lien Term Loan		478,099		10,420		467,679		479,316		10,950		468,366
Second Lien Term Loan		167,000		7,047		159,953		167,000		7,418		159,582
Total debt	$	1,768,849	$	57,409	$	1,711,440	$	1,620,066	$	57,706	$	1,562,360
Less: Debt payable within one year - excluding Netsmart		20,000		497		19,503		28,125		438		27,687
Less: Debt payable within one year - Netsmart		4,866		2,106		2,760		4,866		2,111		2,755
Total long-term debt, less current maturities	$	1,743,983	$	54,806	$	1,689,177	$	1,587,075	$	55,157	$	1,531,918

Interest expense consists of the following:

	Three Months Ended March 31,
(In thousands)	2018		2017
Interest expense	$	7,938	$	4,834
Amortization of discounts and debt issuance costs		3,756		3,581
Netsmart:
Interest expense ⁽¹⁾		12,451		10,917
Amortization of discounts and debt issuance costs		901		848
Total interest expense	$	25,046	$	20,180

⁽¹⁾

Includes interest expense related to capital leases.

Interest expense related to the 1.25% Notes, included in the table above, consists of the following:

	Three Months Ended March 31,
(In thousands)	2018		2017
Coupon interest at 1.25%	$	1,078	$	1,078
Amortization of discounts and debt issuance costs		3,407		3,246
Total interest expense related to the 1.25% Notes	$	4,485	$	4,324

Allscripts Senior Secured Credit Facility

On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), the several banks and other financial institutions or entities from time to time party thereto, and Fifth Third Bank, KeyBank National Association, SunTrust Bank and Wells Fargo Bank, National Association, as syndication agents, amending and restating the Amended and Restated Credit Agreement, dated September 30, 2015, as amended on March 28, 2016 and December 22, 2016 (the “Existing Credit Agreement”). The Second Amended Credit Agreement provides for a $400 million senior secured term loan (an increase from the $250 million term loan provided under the Existing Credit Agreement) (the “Term Loan”) and a $900 million senior secured revolving facility (an increase from the $550 million revolving facility provided under the Existing Credit Agreement) (the “Revolving Facility”), each with a five-year term. The Term Loan is repayable in quarterly installments commencing on June 30, 2018. A total of up to $50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to $100 million of the Revolving Facility could be borrowed under certain foreign currencies. Proceeds from the borrowings under the Second Amended Credit Agreement were used for the refinancing of loans under the Existing Credit Agreement.

The proceeds of the Revolving Facility can be used to finance Allscripts’ working capital needs and for general corporate purposes, including, without limitation, financing of permitted acquisitions, and for share repurchases. Allscripts is also permitted to add one or more incremental revolving and/or term loan facilities in an aggregate amount of up to $600 million, subject to certain conditions (an increase from the $300 million incremental facility permitted under the Existing Credit Agreement).

The initial applicable interest rate margin for Base Rate borrowings is 1.00%, and for Eurocurrency Rate borrowings is 2.00%. On and after September 30, 2018, the interest rate margins will be determined from a pricing table and will depend upon Allscripts’ total leverage ratio. The applicable margins for Base Rate borrowings under the Second Amended Credit Agreement range from 0.50% to 1.25% depending on Allscripts’ total leverage ratio (as compared to the 0.00% to 1.25% range provided under the Existing Credit Agreement). The applicable margins for Eurocurrency Rate loans range from 1.50% to 2.25%, depending on Allscripts’ total leverage ratio (as compared to the 1.00% to 2.25% range provided under the Existing Credit Agreement).

As of March 31, 2018, $400.0 million under the Term Loan, $378.8 million under the Revolving Facility, and $0.8 million in letters of credit were outstanding under the Second Amended Credit Agreement.

As of March 31, 2018, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 2.00%, which totaled 3.88%. We were in compliance with all covenants under the Second Amended Credit Agreement as of March 31, 2018.

As of March 31, 2018, we had $520.4 million available, net of outstanding letters of credit, under our Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of our Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings.

As of March 31, 2018, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount.

Netsmart Non-Recourse Debt

As of March 31, 2018, $478.1 million under the Netsmart First Lien Term Loan, $167.0 million under the Netsmart Second Lien Term Loan and no amounts under the Netsmart Revolving Facility (collectively, the “Netsmart Credit Agreements”) were outstanding.

As of March 31, 2018, the interest rate on the borrowings under the Netsmart First Lien Term Loan was Adjusted LIBO plus 4.50%, which totaled 6.38%, the interest rate on the borrowings under the Netsmart Second Lien Term Loan was Adjusted LIBO plus 9.50%, which totaled 11.38%, and the interest rate on the borrowings under the Netsmart Revolving Facility was Adjusted LIBO plus 4.75%, which totaled 6.63%. Netsmart was in compliance with all covenants under its Netsmart Credit Agreements as of March 31, 2018.

As of March 31, 2018, Netsmart had $50.0 million available, with no outstanding letters of credit commitments, under the Netsmart Revolving Facility. There can be no assurance that Netsmart will be able to draw on the full available balance of the Netsmart Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings.

The following table summarizes future debt payment obligations as of March 31, 2018:


(In thousands)	Total		Remainder of 2018		2019		2020		2021		2022		Thereafter
1.25% Cash Convertible Senior Notes ⁽¹⁾	$	345,000	$	0	$	0	$	345,000	$	0	$	0	$	0
Term Loan		400,000		15,000		20,000		27,500		30,000		37,500		270,000
Revolving Facility ⁽²⁾		378,750		0		0		0		0		0		378,750
Netsmart Non-Recourse Debt ⁽²⁾
First Lien Term Loan ⁽³⁾		478,099		3,650		4,866		4,866		4,866		4,866		454,985
Second Lien Term Loan		167,000		0		0		0		0		0		167,000
Total debt	$	1,768,849	$	18,650	$	24,866	$	377,366	$	34,866	$	42,366	$	1,270,735

⁽¹⁾ Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

⁽²⁾ Assumes no additional borrowings after March 31, 2018, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

⁽³⁾ Starting with the year ended December 31, 2017, additional amounts may be due within 125 days after year-end if Netsmart has “excess cash” as defined in the Netsmart Credit Agreement. For the year ended December 31, 2017, no additional amounts will be due as a result of this provision.

Income Taxes

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

9. Income Taxes

We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes (“ASC 740”). We calculate the quarterly tax provision consistent with the guidance provided by ASC 740-270, whereby we forecast the estimated annual effective tax rate and then apply that rate to the year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. There is no tax benefit recognized on certain of the net operating losses incurred due to insufficient evidence supporting the Company’s ability to use these losses in the future. The effective tax rates were as follows:

	Three Months Ended March 31,
(In thousands)	2018			2017
Loss from continuing operations before income taxes	$	(35,844	)	$	(8,393	)
Income tax benefit (provision)	$	2,914		$	(172	)
Effective tax rate		8.1	%		(2.0	%)

The United States Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017 and introduced significant changes to the income tax law in the United States. Effective in 2018, the Tax Act reduces the United States statutory tax rate from 35% to 21% and creates new taxes on certain foreign-sourced earnings and certain related-party payments, which are referred to as the global intangible low-taxed income tax and the base erosion tax, respectively. In addition, in 2017 we were subject to a one-time transition tax on accumulated foreign subsidiary earnings not previously subject to income tax in the United States.

Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, we made reasonable estimates of the effects and recorded provisional benefit of $20.8 million in our financial statements for the year ended December 31, 2017 in accordance with guidance in Staff Accounting Bulletin No. 118 (SAB 118) which allows a measurement period of up to one year after the enactment date to finalize the recording of the related tax impacts. This provisional benefit includes $26 million benefit for remeasurement of deferred tax balances to reflect the lower federal rate and expense of $5.2 million for the one-time transition tax on accumulated foreign subsidiary earnings not previously subject to income tax in the United States. We will complete our analysis of the Tax Act during 2018, and any needed adjustments to the provisional amounts will be included in income tax expense or benefit in the appropriate period, in accordance with SAB 118. We are continuing to assess the impacts of the Tax Act on the 2018 effective tax rate and income tax accounting, particularly the new Global Intangible Low-taxed Income ("GILTI") tax and Base Erosion and Anti-Abuse Tax (BEAT) rules.

Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended March 31, 2018, compared with the prior year comparable period, differs primarily due to the estimated impact of the GILTI and BEAT provisions and the stricter executive compensation deduction provisions of the Tax Act, reflected in the provision for the three months ended March 31, 2018.

In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Due to the level of forecasted operating income for the year ending December 31, 2018, applied to a pre-tax loss for the three months ended March 31, 2018, we recorded $10.7 million of valuation allowance during the three months ended March 31, 2018 related to deferred tax assets associated with net operating loss carryforwards.

Effective January 1, 2017, we adopted ASU 2016-09. The guidance in ASU 2016-09, among other things, will require all income tax effects of share-based awards to be recognized in the statement of operations when the awards vest or are settled as a discrete item in the period in which they occur. In the three months ended March 31, 2018 and 2017, we recorded $0.9 million and $1.4 million, respectively, of tax expense for awards in which the compensation cost recorded was higher than the tax deductions for the awards. In the quarter ended March 31, 2017, we recorded an offsetting release of valuation allowance in the quarter of $1.4 million. ASU 2016-09 requires entities to recognize excess tax benefits, regardless of whether the tax deduction reduces taxes payable. In the quarter ended March 31, 2017, as part of adopting the new standard, we recorded a gross cumulative effect adjustment of $5.6 million to the opening balance of accumulated deficit to create a deferred tax asset to recognize excess tax benefits not previously recorded. The net decrease to accumulated deficit was $1.8 million due to the recognition of a corresponding valuation allowance of $3.8 million.

Our unrecognized income tax benefits were $12.8 million and $12.0 million as of March 31, 2018 and December 31, 2017, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instruments

3 Months Ended

Mar. 31, 2018

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

10. Derivative Financial Instruments

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

March 31, 2018

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and

other current assets

503

Accrued expenses

Derivatives not subject to hedge accounting:

1.25% Call Option

Other assets

25,410

N/A

1.25% Embedded cash conversion option

N/A

Other liabilities

26,446

Total derivatives

25,913

26,446

December 31, 2017

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and

other current assets

1,136

Accrued expenses

Derivatives not subject to hedge accounting:

1.25% Call Option

Other assets

46,578

N/A

1.25% Embedded cash conversion option

N/A

Other liabilities

47,777

Total derivatives

47,714

47,777

N/A – We define “N/A” as disclosure not being applicable

Foreign Exchange Contracts

We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of March 31, 2018, there were 3 forward contracts outstanding that were staggered to mature monthly starting in April 2018 and ending in June 2018. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond June 2018. As of March 31, 2018, the notional amount of each outstanding forward contract was 120 million INR, or the equivalent of $1.8 million, based on the exchange rate between the United States dollar and the INR in effect as of March 31, 2018. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future.

The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three months ended March 31, 2018, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of March 31, 2018, we estimate that $0.5 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months.

The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss:

	Amount of Gain (Loss) Recognized in OCI (Effective Portion)				Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)
(In thousands)	Three Months Ended March 31, 2018			Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	Three Months Ended March 31, 2018
Foreign exchange contracts	$	(78	)	Cost of Revenue	$	189
				Selling, general and administrative expenses		144
				Research and development	$	222

	Amount of Gain (Loss) Recognized in OCI (Effective Portion)			Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)
(In thousands)	Three Months Ended March 31, 2017		Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	Three Months Ended March 31, 2017
Foreign exchange contracts	$	1,873	Cost of Revenue	$	178
			Selling, general and administrative expenses		137
			Research and development	$	210

1.25% Call Option

In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes.

The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements and Long-term Investments.”

The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal.

1.25% Notes Embedded Cash Conversion Option

The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements and Long-term Investments.”

The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations:

	Three Months Ended March 31,
(In thousands)	2018			2017
1.25% Call Option	$	(21,168	)	$	17,605
1.25% Embedded cash conversion option		21,331			(17,903	)
Net (loss) gain included in other income, net	$	163		$	(298	)

Other Comprehensive Income

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Other Comprehensive Income

11. Other Comprehensive Income

Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains on Foreign Exchange Contracts			Total
Balance as of December 31, 2017 ⁽¹⁾	$	(2,676	)	$	691		$	(1,985	)
Other comprehensive income (loss) before reclassifications		123			(58	)		65
Net losses (gains) reclassified from accumulated other comprehensive loss		0			(261	)		(261	)
Net other comprehensive income		123			(319	)		(196	)
Balance as of March 31, 2018 ⁽²⁾	$	(2,553	)	$	372		$	(2,181	)

^{______________________________________________________}

⁽¹⁾

Net of taxes of $445 thousand for unrealized net gains on foreign exchange contract derivatives.

⁽²⁾

Net of taxes of $131 thousand for unrealized net gains on foreign exchange contract derivatives.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Losses on Available for Sale Securities ⁽¹⁾			Unrealized Net Gains on Foreign Exchange Contracts			Total
Balance as of December 31, 2016 ⁽²⁾	$	(6,028	)	$	(56,420	)	$	619		$	(61,829	)
Other comprehensive (loss) income before reclassifications		1,515			(74,701	)		1,146			(72,040	)
Net losses reclassified from accumulated other comprehensive loss		0			0			(320	)		(320	)
Net other comprehensive (loss) income		1,515			(74,701	)		826			(72,360	)
Balance as of March 31, 2017⁽³⁾	$	(4,513	)	$	(131,121	)	$	1,445		$	(134,189	)

^{____________________________________________________________________________}

⁽¹⁾ Majority of unrealized loss relates to decline in fair value of NantHealth common stock.

⁽²⁾

Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net gains on available for sale securities.

⁽³⁾

Net of taxes of $924 thousand for unrealized net gains on foreign exchange contract derivatives and $60 thousand for unrealized net gains on available for sale securities.

Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”):

	Three Months Ended March 31,
	2018								2017
(In thousands)	Before-Tax Amount			Tax Effect		Net Amount			Before-Tax Amount			Tax Effect			Net Amount
Foreign currency translation adjustments	$	123		$	0	$	123		$	1,515		$	0		$	1,515
Available for sale securities:
Net loss arising during the period		0			0		0			(74,702	)		1			(74,701	)
Net loss reclassified into income		0			0		0			0			0			0
Net change in unrealized gains (losses) on available for sale securities		0			0		0			(74,702	)		1			(74,701	)
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net gains (losses) arising during the period		(78	)		20		(58	)		1,873			(727	)		1,146
Net (gains) losses reclassified into income ⁽¹⁾		(555	)		294		(261	)		(525	)		205			(320	)
Net change in unrealized (losses) gains on foreign exchange contracts		(633	)		314		(319	)		1,348			(522	)		826
Net (loss) gain on cash flow hedges		(633	)		314		(319	)		1,348			(522	)		826
Other comprehensive income (loss)	$	(510	)	$	314	$	(196	)	$	(71,839	)	$	(521	)	$	(72,360	)

____________________________________________

⁽¹⁾

Tax effects for the three months ended March 31, 2018 include $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.

Contingencies	3 Months Ended
Contingencies	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us. The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff sought $500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be willful, knowing or intentional, and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. On March 31, 2016, plaintiff filed its motion for class certification. On May 31, 2016, we filed our opposition to plaintiff’s motion for class certification, and simultaneously moved for summary judgment on all of plaintiff’s claims. On June 2, 2017, an order was entered denying class certification and, accordingly, the case will not proceed on a class-wide basis. The EIS Business acquired from McKesson on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. McKesson has agreed, with respect to the CID, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. The CID relates to the certification of Practice Fusion’s software under the U.S. Office of the National Coordinator for Health Information Technology’s electronic health record certification program, and related business practices. It has been Practice Fusion’s practice to respond to such matters in a cooperative, thorough and timely manner. To date, the CID has not led to a claim or legal proceeding against Practice Fusion. On January 25, 2018, a complaint was filed in Surfside Non-Surgical Orthopedics, P.A. v. Allscripts Healthcare Solutions, Inc., No. 1:18-cv-00566, in the Northern District of Illinois. This is a purported class action lawsuit related to a January 18, 2018 ransomware attack, and alleges the following counts: (1) negligence, gross negligence and negligence per se; (2) breach of contract; (3) unjust enrichment; (4) violation of the Illinois Consumer Fraud Act; and (5) violation of the Illinois Deceptive Trade Practices Act. Plaintiff seeks to represent a class of customers seeking damages from Allscripts. The parties are currently engaged in limited jurisdictional discovery. Allscripts expects to respond to the complaint after this discovery is completed.

Discontinued Operations

3 Months Ended

Mar. 31, 2018

Discontinued Operations And Disposal Groups [Abstract]

Discontinued Operations

13. Discontinued Operations

Two of the product offerings acquired with the EIS Business, Horizon Clinicals and Series2000 Revenue Cycle, are to be sunset after the first quarter of 2018. The decision to discontinue these solutions was made prior to our acquisition of the EIS Business and, therefore, are presented below as discontinued operations. Until the end of the first quarter of 2018, we will be involved in ongoing maintenance and support for these solutions until customers have transitioned to other platforms. No disposal gains or losses were recognized during the three months ended March 31, 2018 related to this discontinued operation.

The following table summarizes the major classes of assets and liabilities of the discontinued operation, as reported on the consolidated balance sheet as of March 31, 2018:


(In thousands)	March 31, 2018		December 31, 2017
Carrying amounts of major classes of assets included as part of discontinued operations:
Accounts receivable, net	$	2,265	$	8,196
Prepaid expenses and other current assets		2,680		3,080
Total assets attributable to discontinued operations	$	4,945	$	11,276

Carrying amounts of major classes of liabilities included as part of discontinued operations:
Accounts payable	$	104	$	114
Accrued expenses		6,150		5,599
Accrued compensation and benefits		8,022		7,728
Deferred revenue		0		7,241
Other classes of liabilities that are not major		0		676
Total liabilities attributable to discontinued operations	$	14,276	$	21,358

The following table summarizes the major classes of line items constituting income (loss) of the discontinued operation, as reported in the consolidated statements of operations for the three months ended March 31, 2018:

	Three months ended
(In thousands)	March 31, 2018
Major classes of line items constituting pretax profit (loss) of discontinued operations
Revenue:
Software delivery, support and maintenance	$	9,804
Client services		492
Total revenue		10,296
Cost of revenue:
Software delivery, support and maintenance		2,463
Client services		743
Total cost of revenue		3,206
Gross profit		7,090
Selling, general and administrative expenses		0
Research and development		1,124
Income from discontinued operations before income taxes		5,966
Income tax provision		(1,551	)
Income from discontinued operations, net of tax	$	4,415

During the three months ended March 31, 2018, the discontinued operation generated $4.3 million of cash.

Business Segments

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Business Segments

14. Business Segments

We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management.

During the first quarter of 2018, in an effort to further streamline and align our operating structure around our key acute and population health management solutions, we made several changes to our organizational and reporting structure. These changes included the split of our former Population Health operating segment into several components. The dbMotion business unit, formerly included in the Population Health operating segment, is now aligned with the Hospitals and Health Systems operating segment within the Clinical and Financial solutions reportable segment. The Care Management, Referral Management and Careport business units, formally included in the Population Health operating segment, were combined into a new CarePort operating segment within the Population Health reportable segment. The prior period segment disclosures below were revised to conform to the current year presentation.

As of March 31, 2018, we had ten operating segments, which are aggregated into three reportable segments. The Clinical and Financial Solutions reportable segment includes the Hospitals and Health Systems, Ambulatory, Payer and Life Sciences, and EIS-Classics strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include EHR-related software, connectivity and coordinated care solutions, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of five separate operating segments: CarePort, FollowMyHealth^®, EPSi^TM, EIS-EWS and NantHealth. This reportable segment derives its revenue from the sale of health management, financial management and patient engagement solutions, which are mainly targeted at hospitals, health systems, other care facilities and Accountable Care Organizations (“ACOs”). These solutions enable clients to transition, analyze and coordinate care across the entire care community. This segment also provides document, content and supply chain management solutions through the EIS-EWS operating segment. Refer to Note 2, “Business Combinations” and Note 16, “Subsequent Events” for additional information regarding the sale of the strategic sourcing and OneContent business units, respectively, which together comprise a substantial majority of the EIS-EWS operating segment. The Netsmart reportable segment is comprised of the Netsmart strategic business unit, which represents a separate operating segment. Netsmart operates in the home care and behavioral healthcare information technology field throughout the United States and provides software and technology solutions to the health and human services industry, which comprises behavioral health, addiction treatment, intellectual and developmental disability services, child and family services, and public health segment, as well as to post-acute home care organizations.

The results of operations related to two of the product offerings acquired with the EIS Business are presented throughout these financial statements as discontinued operations and are included in the Clinical and Financial Solutions reportable segment, except for acquisition-related deferred revenue adjustments, which are included in “Unallocated Amounts”. Refer to Note 13, “Discontinued Operations”.

Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions on allocation of resources. With the exception of the Netsmart segment, in determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. With the exception of the Netsmart segment, we also exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware, other than the respective amounts associated with the Netsmart segment. The Netsmart segment, as presented, includes all revenue and expenses incurred by Netsmart since it operates as a stand-alone business entity and its resources allocation and performance are reviewed and measured at such all-inclusive level. The eliminations of intercompany transactions between Allscripts and Netsmart are included in the “Unallocated Amounts” category. We do not track our assets by segment.

	Three Months Ended March 31,
(In thousands)	2018			2017
Revenue:
Clinical and Financial Solutions	$	373,979		$	296,180
Population Health		69,705			43,429
Netsmart		82,486			73,007
Unallocated Amounts		(1,948	)		859
Discontinued Operations		(10,296	)		0
Total revenue	$	513,926		$	413,475

Gross Profit:
Clinical and Financial Solutions	$	154,286		$	119,261
Population Health		53,371			35,845
Netsmart		36,301			34,574
Unallocated Amounts		(15,893	)		(11,028	)
Discontinued Operations		(7,090	)		0
Total gross profit	$	220,975		$	178,652

Income (loss) from operations:
Clinical and Financial Solutions	$	70,742		$	53,582
Population Health		36,434			28,468
Netsmart		2,313			8,929
Unallocated Amounts		(107,843	)		(79,716	)
Discontinued Operations		(5,966	)		0
Total income from operations	$	(4,320	)	$	11,263

Supplemental Disclosures

3 Months Ended

Mar. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Disclosures

15. Supplemental Disclosures

Restricted Cash

The majority of the restricted cash balance as of March 31, 2018 represents Netsmart’s cash deposits to maintain two letters of credit with a financial institution related to customer agreements and an escrow fund related to a previous acquisition associated with the acquired EIS Business.

	Three Months Ended March 31,
(In thousands)	2018		2017
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	135,003	$	104,391
Restricted cash		8,769		-
Total cash, cash equivalents and restricted cash	$	143,772	$	104,391

Supplemental non-cash information:
Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	$	12,149	$	10,962
Obligations incurred to purchase capitalized software or enter into capital leases	$	9,786	$	1,407
Contribution of assets in exchange for equity interest	$	4,000	$	0

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events Completion of OneContent business divestiture On April 2, 2018, Allscripts, Healthcare LLC and certain subsidiaries of Healthcare LLC and Hyland Software, Inc., an Ohio corporation (“Hyland”), completed the transactions contemplated by an Asset Purchase Agreement (the “Asset Purchase Agreement”) by which Hyland acquired substantially all of the assets of the Allscripts’ business providing hospitals and health systems document and other content management software and services generally known as “OneContent”. Allscripts acquired the OneContent business during the fourth quarter of 2017 through the acquisition the EIS Business. Certain assets of Allscripts relating to the OneContent business were excluded from the transaction and retained by Allscripts, as described in the Asset Purchase Agreement. In addition, Hyland assumed certain liabilities related to the OneContent business under the terms of the Asset Purchase Agreement. The total consideration for the OneContent business is $260 million, which is subject to certain adjustments for liabilities assumed by the Hyland and net working capital as described in the Asset Purchase Agreement. Membership Interest Purchase Agreement On April 5, 2018, ECS Acquisition Co. LLC, a Delaware limited liability company (the Purchaser) and a wholly-owned subsidiary of Netsmart, Change Healthcare Technologies, LLC, a Delaware limited liability company (CHT), and Change Healthcare Holdings, LLC, a Delaware limited liability company (CHC and, together with CHT, the Sellers), entered into a Membership Interest Purchase Agreement (the Purchase Agreement). Pursuant to, and subject to the terms and conditions of, the Purchase Agreement, Purchaser will purchase (the Acquisition) all issued and outstanding membership interests of Barista Operations, LLC, a Delaware limited liability company, which entity, as of the closing of the Acquisition, will own and operate the extended care solutions business of Sellers and their subsidiaries providing information technology solutions and services to the Care at Home industry, which comprises the Extended Care Solutions business of McKesson Technology Solutions that was contributed to CHC by McKesson Corporation effective March 1, 2017. The purchase price for the Acquisition will be $167.5 million, subject to adjustments for net working capital, and will be funded with borrowings under the Netsmart Credit Agreements. $2.5 million of the purchase price will be deposited into escrow at the closing of the Acquisition and will be subject to release to the Sellers or to the Purchaser as described below. Completion of the Acquisition is subject to customary conditions, including (i) the expiration or termination of the waiting period applicable to consummation of the Acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1975, as amended, (ii) the absence of any law, order or injunction prohibiting the closing of the Acquisition, (iii) the accuracy of the other party’s representations and warranties (subject to customary materiality qualifiers), (iv) each party having performed in all material respects all of its obligations under the Purchase Agreement and (v) no occurrence of a Material Adverse Effect (as defined in the Purchase Agreement) since the execution of the Purchase Agreement. The Purchase Agreement may be terminated by Purchaser or Sellers under certain circumstances, including if the Acquisition is not consummated by October 5, 2018 (provided that, if the Acquisition has not closed as of such date solely because of the failure to satisfy the condition described in clause (i) or clause (ii) above, such date may be extended by either party until January 7, 2019). There is no financing condition to the consummation of the Acquisition. The Purchase Agreement also contemplates that CHC will provide certain transition services to Purchaser pursuant to a transition services agreement. Additionally, the Purchase Agreement contemplates that CHC and Netsmart Technologies will negotiate in good faith and use commercially reasonable efforts to enter into certain commercial arrangements pursuant to which, among other things, Netsmart Technologies will market and sell certain products of CHC. The $2.5 million of the purchase price deposited in escrow at closing will be distributed to CHC and the Purchaser based on the achievement of certain revenue thresholds. Agreement to Acquire HealthGrid On April 27, 2018, Allscripts, Healthcare LLC and FollowMyHealth Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and wholly-owned subsidiary of Healthcare LLC, entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Healthcare LLC, Merger Sub, Health Grid Holding Company, a Delaware corporation (the “Health Grid”), and Raj Toleti as Representative, whereby Healthcare LLC will acquire all of the issued and outstanding shares of capital stock of Health Grid through the merger (the “Merger”) of Merger Sub with and into Health Grid, with Health Grid surviving the Merger as a wholly-owned subsidiary of Healthcare LLC. The purchase price for the Merger is $60 million in cash plus up to an aggregate of $50 million in earnout payments based on Health Grid achieving certain revenue targets over the next three years (subject to adjustments for net working capital, cash, debt and transaction expenses). The Merger is expected to close in the second quarter of 2018, subject to the satisfaction of customary closing conditions.

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2018 and 2017 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the full year ending December 31, 2018. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Change in Presentation	Change in Presentation During the first quarter of 2018, we changed the presentation of certain bundled revenue streams. Such revenue was previously included as part of software delivery, support and maintenance revenue. Under the new presentation, such revenue is included as part of client services revenue. The revenue previously reported for the first quarter of 2017 has been recast to match the new presentation by reducing software delivery, support and maintenance and increasing client services by $4.3 million.
Significant Accounting Policies	Significant Accounting Policies We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) effective on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. There have been no other changes to our significant accounting policies from those disclosed in our Form 10-K.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The amendments in ASU 2016-01 modify the requirements related to the measurement of certain financial instruments in the statement of financial condition and results of operation. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee), are required to be measured at fair value with changes in fair value recognized in net income. An entity may continue to elect to measure equity investments which do not have a readily determinable fair value at cost with adjustments for impairment, if any, and observable changes in price. In addition, for a liability (other than a derivative liability) that an entity measures at fair value, any change in fair value related to the instrument-specific credit risk, (i.e., the entity’s own credit risk), should be presented separately in other comprehensive income and not as a component of net income. ASU 2016-01 also clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for interim and annual periods beginning after December 15, 2017 with early adoption permitted solely for the instrument-instrument specific credit risk for liabilities measured at fair value. The amendments should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption. We adopted ASU 2016-01 effective January 1, 2018 and there was no immediate impact upon adoption. Refer to Note 3, “Fair Value Measurements”, for additional information regarding our unconsolidated equity investments. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). ASU 2017-01 provides new accounting guidance to assist an entity in evaluating when a set of transferred assets and activities is a business. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, and should be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We adopted ASU 2017-01 effective January 1, 2018 and there was no immediate impact upon adoption.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) intended to improve financial reporting about leasing transactions. The new guidance will require entities that lease assets to recognize on their balance sheets the assets and liabilities for the rights and obligations created by those leases and to disclose key information about the leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. We are currently evaluating the impact of this accounting guidance, including the timing of adoption. In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”), which provides new accounting guidance to simplify the accounting for goodwill impairment. ASU 2017-04 removes Step Two of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the new guidance, a goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill assigned to the reporting unit. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. ASU 2017-04 is effective for annual and interim periods in fiscal years beginning after December 15, 2019 with early adoption permitted for any goodwill impairment tests performed after January 1, 2017. The new guidance is to be applied prospectively. We are currently evaluating the impact of this accounting guidance, including the timing of adoption. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”), which provides new accounting guidance to simplify and improve the reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in this Update make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted in any interim period after the issuance of this Update. We are currently evaluating the impact of this accounting guidance, including the timing of adoption. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of Supplemental Proforma Results

(In thousands, except per share amounts)	Three Months Ended March 31, 2017
Supplemental pro forma data for combined entity:
Revenue	$	520,810
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(17,572	)
Loss per share, basic and diluted	$	(0.10	)

Practice Fusion, Inc. [Member]

Schedule of Consideration Funded by Sources of Funds

The consideration paid for Practice Fusion is shown below:

	(In thousands)
Aggregate purchase price	$	100,000
Add: Net working capital surplus		469
Less: Adjustment for assumed indebtedness		(1,684	)
Add: Closing cash		14,951
Total consideration paid for Practice Fusion	$	113,736

Assets Acquired and Liabilities Assumed

	(In thousands)
Cash and cash equivalents	$	14,951
Accounts receivable, net		13,397
Prepaid expenses and other current assets		809
Fixed assets		1,764
Intangible assets		67,200
Goodwill		34,739
Other assets		43
Accounts payable and accrued expenses		(7,620	)
Deferred revenue		(2,400	)
Long-term deferred tax liability		(8,332	)
Other liabilities		(815	)
Net assets acquired	$	113,736

Acquired Intangible Assets Amortization

The following table summarizes the preliminary fair values of the identifiable intangible assets and their estimated useful lives:

	Useful Life	Fair Value
Description	(In years)	(In thousands)
Customer Relationships - Physician Practices	15	$	28,700
Customer Relationships - Pharmaceutical Partners	20		19,800
Technology	8		14,800
Tradenames	10		3,900
		$	67,200

Fair Value Measurements and Long-term Investments (Tables)

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:

	Balance Sheet	March 31, 2018										December 31, 2017
(In thousands)	Classifications	Level 1		Level 2		Level 3			Total			Level 1		Level 2		Level 3			Total
1.25% Call Option	Other assets	$	0	$	0	$	25,410		$	25,410		$	0	$	0	$	46,578		$	46,578
1.25% Embedded cash conversion option	Other liabilities		0		0		(26,446	)		(26,446	)		0		0		(47,777	)		(47,777	)
Foreign exchange derivative assets	Prepaid expenses and other current assets		0		503		0			503			0		1,136		0			1,136
Total		$	0	$	503	$	(1,036	)	$	(533	)	$	0	$	1,136	$	(1,199	)	$	(63	)

Summary of Long-term Equity Investments Included in Other Assets

The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets:

	Number of
	Investees		Original		Carrying Value at
(In thousands, except # of investees)	at March 31, 2018		Investment		March 31, 2018		December 31, 2017
Equity method investments ⁽¹⁾		4	$	5,658	$	7,197	$	3,258
Cost method investments		7		32,784		21,820		26,755
Total equity investments		11	$	38,442	$	29,017	$	30,013

_________________________________

⁽¹⁾

Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Stock-Based Compensation Expense (Benefit)

	Three Months Ended March 31,
(In thousands)	2018		2017
Cost of revenue:
Software delivery, support and maintenance	$	616	$	1,125
Client services		1,436		1,572
Total cost of revenue		2,052		2,697
Selling, general and administrative expenses		7,245		3,550
Research and development		2,841		2,589
Total stock-based compensation expense	$	12,138	$	8,836

Stock-Based Awards Granted

We granted stock-based awards as follows:

	Three Months Ended March 31, 2018
			Weighted-Average
			Grant Date
(In thousands, except per share amounts)	Shares		Fair Value
Service-based restricted stock units		1,300	$	14.20
Performance-based restricted stock units with a service condition		524	$	15.74
Market-based restricted stock units with a service condition		0	$	0.00
		1,824	$	14.64

Earnings (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Calculations of Earnings (Loss) Per Share

The calculations of earnings (loss) per share are as follows:

	Three Months Ended March 31,
(In thousands, except per share amounts)	2018			2017
Basic Loss per Common Share:
(Loss) income from continuing operations, net of tax	$	(32,930	)	$	(8,565	)
Less: Net loss (income) attributable to non-controlling interests		790			(453	)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart		(12,149	)		(10,962	)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(44,289	)	$	(19,980	)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		4,415			0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(39,874	)	$	(19,980	)

Weighted-average common shares outstanding		179,882			180,767

Basic Loss from continuing operations per Common Share	$	(0.25	)	$	(0.11	)
Basic Income from discontinued operations per Common Share		0.03			0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.22	)	$	(0.11	)

Diluted Loss per Common Share:
(Loss) income from continuing operations, net of tax	$	(32,930	)	$	(8,565	)
Less: Net loss (income) attributable to non-controlling interests		790			(453	)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart		(12,149	)		(10,962	)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(44,289	)	$	(19,980	)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		4,415			0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(39,874	)	$	(19,980	)

Weighted-average common shares outstanding		179,882			180,767
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants		0			0
Weighted-average common shares outstanding assuming dilution		179,882			180,767

Diluted Loss from continuing operations per Common Share	$	(0.25	)	$	(0.11	)
Diluted Income from discontinued operations per Common Share		0.03			0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.22	)	$	(0.11	)

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share

Three Months Ended

March 31,

(In thousands)

2018

2017

Shares subject to anti-dilutive stock options, restricted stock

unit awards and warrants excluded from calculation

23,208

26,689

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:

	March 31, 2018							December 31, 2017
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	693,844	$	(419,081	)	$	274,763	$	695,354	$	(405,114	)	$	290,240
Customer contracts and relationships		948,703		(475,407	)		473,296		922,492		(464,860	)		457,632
Total	$	1,642,547	$	(894,488	)	$	748,059	$	1,617,846	$	(869,974	)	$	747,872

Intangibles not subject to amortization:
Registered trademarks						$	79,000						$	79,000
Goodwill							2,051,437							2,004,953
Total						$	2,130,437						$	2,083,953

Changes in Carrying Amount of Goodwill

Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2018 were as follows:

	Clinical and			Population
(In thousands)	Financial Solutions			Health			Netsmart		Total
Balance as of December 31, 2017	$	861,615		$	431,132		$	712,206	$	2,004,953
Additions arising from business acquisitions:
Practice Fusion acquisition		34,739			0			0		34,739
Other acquisitions		4,829			0			1,374		6,203
Total arising from business acquisitions		39,568			0			1,374		40,942
Increases (decreases) due to measurement period adjustments:
NantHealth provider/patient solutions business		0			117			0		117
Enterprise Information Solutions business		9,204			28,454			0		37,658
Other measurement period adjustments		(205	)		0			0		(205	)
Total increases (decreases) due to measurement period adjustments:		8,999			28,571			0		37,570
Total additions to goodwill		48,567			28,571			1,374		78,512
Divestitures		(30,105	)		(2,198	)		0		(32,303	)
Foreign exchange translation		275			0			0		275
Balance as of March 31, 2018	$	880,352		$	457,505		$	713,580		2,051,437

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2018

Revenue Recognized Related To Various Performance Obligations And Elected Accounting Expedients

The breakdown of revenue recognized related to various performance obligations and elected accounting expedients is presented in the table below:


(In thousands)	Three Months Ended March 31, 2018
Revenue related to deferred revenue balance at beginning of period	$	204,297
Revenue related to new performance obligations satisfied during the period		257,222
Revenue recognized under "right-to-invoice" expedient		49,638
Reimbursed travel expenses, shipping and other revenue		2,769
Total revenue	$	513,926

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments:

	Three Months Ended March 31,
(In thousands)	2018		2017
Revenue:
Software delivery, support and maintenance
Recurring revenue	$	294,455	$	227,450
Non-recurring revenue		35,311		40,738
Total software delivery, support and maintenance		329,766		268,188
Client services
Recurring revenue	$	122,474	$	101,779
Non-recurring revenue		61,686		43,508
Total client services		184,160		145,287
Total revenue	$	513,926	$	413,475

	Three Months Ended March 31, 2018
(In thousands)	Clinical and Financial Solutions		Population Health		Netsmart		Unallocated			Discontinued Operations			Total
Software delivery, support and maintenance	$	230,557	$	61,198	$	49,245	$	1,165		$	(12,399	)	$	329,766
Client services		143,422		8,507		33,241		(3,113	)		2,103			184,160
Total revenue	$	373,979	$	69,705	$	82,486	$	(1,948	)	$	(10,296	)	$	513,926



	Three Months Ended March 31, 2017
(In thousands)	Clinical and Financial Solutions		Population Health		Netsmart		Unallocated			Discontinued Operations			Total
Software delivery, support and maintenance	$	178,330	$	39,689	$	46,496	$	3,673		$	0		$	268,188
Client services		117,850		3,741		26,511		(2,815	)		0			145,287
Total revenue	$	296,180	$	43,430	$	73,007	$	858		$	0		$	413,475

ASC 606

Impact of Adoption of ASC 606 on Financial Statements

The following adjustments were made to balances previously reported on the condensed consolidated balance sheet as of December 31, 2017:

	As Reported			Adjustments			Adjusted
(In thousands, except per share amounts)	December 31, 2017			due to ASC 606			January 1, 2018
Accounts receivable, net	$	567,873		$	(32,529	)	$	535,344
Contract assets		0			76,509			76,509
Prepaid expenses and other current assets		115,463			11,646			127,109

Deferred revenue, current		546,830			(7,453	)		539,377
Deferred revenue, long-term		24,047			0			24,047
Deferred taxes, net		93,643			16,478			110,121
Accumulated deficit		(338,150	)		46,601			(291,549	)

The following tables compare the reported consolidated balance sheet and statement of operations as of and for the three months ended March 31, 2018, to the pro-forma amounts assuming the previous guidance of ASC 605 had been in effect:

	March 31, 2018
(In thousands, except per share amounts)	As reported under ASC 606			Adjustments due to ASC 606			Pro forma under ASC 605
Accounts receivable, net	$	495,695		$	78,302		$	573,997
Contract assets		45,068			(45,068	)		0
Prepaid expenses and other current assets		130,051			33			130,084
Contract assets - long-term		40,486			(40,486	)		0

Deferred revenue, current		540,289			(972	)		539,317
Deferred taxes, net		117,061			(1,629	)		115,432
Accumulated deficit		(319,271	)		(4,618	)		(323,889	)

	Three Months Ended March 31, 2018
(In thousands, except per share amounts)	As reported under ASC 606			Adjustments due to ASC 606			Pro forma under ASC 605
Software delivery, support and maintenance	$	329,766		$	(5,028	)	$	324,738
Client services		184,160			(1,066	)		183,094
Gross profit		220,975			(6,279	)		214,696
Selling, general and administrative expenses		143,070			(218	)		142,852
Loss from operations		(4,320	)		(6,061	)		(10,381	)
Loss from continuing operations before income taxes		(35,844	)		(6,247	)		(42,091	)
Income tax benefit		2,914			1,629			4,543
Net loss		(28,515	)		(4,618	)		(33,133	)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(39,874	)		(4,618	)	$	(44,492	)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(0.22	)		(0.03	)	$	(0.25	)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(0.22	)		(0.03	)	$	(0.25	)

Debt (Tables)

3 Months Ended

Mar. 31, 2018

Business Combinations - Acquisition of Practice Fusion, Inc - Additional Information (Detail) - USD ($)		3 Months Ended
	Feb. 13, 2018	Mar. 31, 2018
Business Acquisition [Line Items]
Goodwill expected to be tax deductible		$ 0
Practice Fusion, Inc. [Member]
Business Acquisition [Line Items]
Date of acquisition	Feb. 13, 2018
Business combination, aggregate consideration	$ 113,736,000
Practice Fusion, Inc. [Member] \| Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition-related costs		$ 500,000

Schedule of Consideration Transaction (Detail) - Practice Fusion, Inc. [Member] $ in Thousands	Feb. 13, 2018 USD ($)
Business Acquisition [Line Items]
Aggregate purchase price	$ 100,000
Add: Net working capital surplus	469
Less: Adjustment for assumed indebtedness	(1,684)
Add: Closing cash	14,951
Business combination, aggregate consideration	$ 113,736

Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Feb. 13, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 2,051,437		$ 2,004,953
Practice Fusion, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 14,951
Accounts receivable, net		13,397
Prepaid expenses and other current assets		809
Fixed assets		1,764
Intangible assets		67,200
Goodwill		34,739
Other assets		43
Accounts payable and accrued expenses		(7,620)
Deferred revenue		(2,400)
Long-term deferred tax liability		(8,332)
Other liabilities		(815)
Net assets acquired		$ 113,736

Acquired Intangible Assets Amortization (Detail) - Practice Fusion, Inc. [Member] $ in Thousands	Feb. 13, 2018 USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 67,200
Customer Relationships - Physician Practices [Member]
Business Acquisition [Line Items]
Description	15 years
Customer Relationships	$ 28,700
Customer Relationships - Pharmaceutical Partners [Member]
Business Acquisition [Line Items]
Description	20 years
Customer Relationships	$ 19,800
Technology [Member]
Business Acquisition [Line Items]
Description	8 years
Customer Relationships	$ 14,800
Tradenames [Member]
Business Acquisition [Line Items]
Description	10 years
Customer Relationships	$ 3,900

Business Combinations - Other Acquisitions and Divestiture - Additional Information (Detail) - USD ($)				1 Months Ended	3 Months Ended
	Feb. 06, 2018	Jan. 31, 2018	Oct. 02, 2017	Apr. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Cash paid for business acquisitions					$ 109,020,000	$ 3,975,000
Goodwill					2,051,437,000		$ 2,004,953,000
Goodwill expected to be tax deductible					0
Equity method investments					$ 7,197,000		$ 3,258,000
Unit Purchase Agreement [Member]
Business Acquisition [Line Items]
Goodwill		$ 1,400,000
Date of acquisition agreement date		Jan. 31, 2018
Business combination, aggregate consideration		$ 5,400,000
Consideration paid in cash		$ 2,000,000
Ownership percentage acquired		100.00%
Business combination consideration remaining amount payable		$ 3,600,000
Cloud-based Analytics Software Platform Provider [Member]
Business Acquisition [Line Items]
Date of acquisition	Feb. 06, 2018
Cash paid for business acquisitions	$ 8,000,000
Goodwill	4,800,000
Accounts receivable, net	800,000
Liabilities assumed, account payable	200,000
Liabilities assumed, deferred revenue	600,000
Liabilities assumed, deferred tax liabilities net	1,100,000
Goodwill expected to be tax deductible	0
Cloud-based Analytics Software Platform Provider [Member] \| Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets	3,700,000
Description					8 years
Cloud-based Analytics Software Platform Provider [Member] \| Customer Relationships
Business Acquisition [Line Items]
Intangible assets	$ 600,000
Description					1 year
EIS Business [Member]
Business Acquisition [Line Items]
Business combination, aggregate consideration			$ 185,000,000
Effective date of divestiture					March 15, 2018
Minority interest percentage					35.70%
Equity method investments					$ 4,000,000
EIS Business [Member] \| Subsequent Event [Member]
Business Acquisition [Line Items]
Business combination, aggregate consideration				$ 2,700,000
EIS Business [Member] \| Other (Loss) Income [Member]
Business Acquisition [Line Items]
Loss on investment					$ 900,000

Business Combinations - Acquisition of DeVero - Additional Information (Detail) - USD ($)		3 Months Ended
	Jul. 17, 2017	Mar. 31, 2018	Mar. 31, 2017
Business Acquisition [Line Items]
Cash paid for business acquisitions		$ 109,020,000	$ 3,975,000
Netsmart [Member] \| DeVero Inc [Member]
Business Acquisition [Line Items]
Date of acquisition	Jul. 17, 2017
Cash paid for business acquisitions	$ 50,500,000
Measurement period adjustments recorded		$ 0

Business Combinations - Acquisition of the Patient/Provider Engagement Solutions Business from NantHealth, Inc. - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Business Acquisition [Line Items]
Goodwill Purchase Accounting Adjustments	$ 37,570
NantHealth, Inc. [Member]
Business Acquisition [Line Items]
Date of acquisition	Aug. 25, 2017
Goodwill Purchase Accounting Adjustments	$ 117

Business Combinations and Other Investments - Acquisition of the Enterprise Information Solutions Business from McKesson Corporation - Additional Information (Detail) $ in Thousands		3 Months Ended
	Oct. 02, 2017 USD ($) Subsidiary	Mar. 31, 2018 USD ($)
Business Acquisition [Line Items]
Goodwill Purchase Accounting Adjustments		$ 37,570
EIS Business [Member]
Business Acquisition [Line Items]
Number of wholly owned subsidiaries in which outstanding equity interest acquired \| Subsidiary	2
Business combination, aggregate consideration	$ 185,000
Goodwill Purchase Accounting Adjustments		37,658
Increase in deferred revenue		44,000
Increases in identified intangible assets		$ 6,600

Business Combinations - Formation of Joint Business Entity and Acquisition of Netsmart, Inc - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended
	Apr. 19, 2016	Mar. 31, 2018
Business Acquisition [Line Items]
Contribution and investment agreement date		Mar. 20, 2016
Homecare Business [Member]
Business Acquisition [Line Items]
Escrow deposit related to the integration of homecare business	$ 15.0	$ 9.0
Escrow deposit period	5 years
Netsmart [Member]
Business Acquisition [Line Items]
Netsmart transaction completion date		Apr. 19, 2016

Pro forma Results (Detail) - Combined Entity [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) $ / shares
Business Acquisition [Line Items]
Revenue	$ 520,810
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (17,572)
Loss per share, basic and diluted \| $ / shares	$ (0.10)

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 130,051	$ 115,463
Total	(533)	(63)
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	503	1,136
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(26,446)	(47,777)
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	25,410	46,578
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	0	0
Level 1 [Member] \| Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] \| 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] \| 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	503	1,136
Level 2 [Member] \| Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	503	1,136
Level 2 [Member] \| 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] \| 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	(1,036)	(1,199)
Level 3 [Member] \| Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] \| 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(26,446)	(47,777)
Level 3 [Member] \| 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 25,410	$ 46,578

Fair Value Measurements and Long-term Investments - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Non-cash impairment charge of investments	$ 5.5
Cost basis of cost-method equity investments	4.9
Cost basis of note receivable prior to impairment	$ 2.6
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Nov. 17, 2016
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0		$ 0
Stock options granted	0		0
Share issued, exercise of options and release of stock awards	1,300,000			1,300,000
Shares settled for tax withholding	609,000		494,000
Common stock repurchased, amount	$ 57,599,000		$ 0
Netsmart [Member]
Class Of Stock [Line Items]
Stock options granted	0
Stock based compensation expense (benefit)	$ 1,200		$ (3,500)
Liability for outstanding awards	$ 9,200,000
Estimated weighted average fair value, Black-Scholes-Merton option pricing model	$ 0.30				$ 0.54
November 2016 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount						$ 200,000,000
Common stock repurchased, shares		4,100,000
Common stock repurchased, amount		$ 57,600,000
Approximate value of common stock shares yet to be purchased under the stock repurchase program		$ 106,400,000

Stock-Based Compensation Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 12,138	$ 8,836
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	2,052	2,697
Cost of revenue [Member] \| Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	616	1,125
Cost of revenue [Member] \| Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,436	1,572
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	7,245	3,550
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 2,841	$ 2,589

Stock-Based Awards Granted (Detail) shares in Thousands	3 Months Ended
Stock-Based Awards Granted (Detail) shares in Thousands	Mar. 31, 2018 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted \| shares	1,824
Weighted-Average Grant Date Fair Value, granted \| $ / shares	$ 14.64
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted \| shares	1,300
Weighted-Average Grant Date Fair Value, granted \| $ / shares	$ 14.20
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted \| shares	524
Weighted-Average Grant Date Fair Value, granted \| $ / shares	$ 15.74
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted \| shares	0
Weighted-Average Grant Date Fair Value, granted \| $ / shares	$ 0.00

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Basic Loss per Common Share:
(Loss) income from continuing operations, net of tax	$ (32,930)	$ (8,565)
Less: Net loss (income) attributable to non-controlling interests	790	(453)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(12,149)	(10,962)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	(44,289)	(19,980)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	4,415	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (39,874)	$ (19,980)
Weighted-average common shares outstanding	179,882	180,767
Continuing operations	$ (0.25)	$ (0.11)
Discontinued operations	0.03	0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.22)	$ (0.11)
Diluted Loss per Common Share:
(Loss) income from continuing operations, net of tax	$ (32,930)	$ (8,565)
Less: Net loss (income) attributable to non-controlling interests	790	(453)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(12,149)	(10,962)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	(44,289)	(19,980)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	4,415	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (39,874)	$ (19,980)
Weighted-average common shares outstanding	179,882	180,767
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants	0	0
Weighted-average common shares outstanding assuming dilution	179,882	180,767
Continuing operations	$ (0.25)	$ (0.11)
Discontinued operations	0.03	0.00
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.22)	$ (0.11)

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,642,547	$ 1,617,846
Accumulated Amortization	(894,488)	(869,974)
Intangible Assets, Net	748,059	747,872
Registered trademarks	79,000	79,000
Goodwill	2,051,437	2,004,953
Total	2,130,437	2,083,953
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	693,844	695,354
Accumulated Amortization	(419,081)	(405,114)
Intangible Assets, Net	274,763	290,240
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	948,703	922,492
Accumulated Amortization	(475,407)	(464,860)
Intangible Assets, Net	$ 473,296	$ 457,632

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Goodwill [Line Items]
Goodwill	$ 2,004,953
Additions arising from business acquisitions	40,942
Total increases (decreases) due to measurement period adjustments:	37,570
Total additions to goodwill	78,512
Divestitures	(32,303)
Foreign exchange translation	275
Goodwill, net	2,051,437
Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	34,739
Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	6,203
Total increases (decreases) due to measurement period adjustments:	(205)
NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	117
EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	37,658
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	861,615
Additions arising from business acquisitions	39,568
Total increases (decreases) due to measurement period adjustments:	8,999
Total additions to goodwill	48,567
Divestitures	(30,105)
Foreign exchange translation	275
Goodwill, net	880,352
Clinical and Financial Solutions [Member] \| Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	34,739
Clinical and Financial Solutions [Member] \| Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	4,829
Total increases (decreases) due to measurement period adjustments:	(205)
Clinical and Financial Solutions [Member] \| NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	0
Clinical and Financial Solutions [Member] \| EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	9,204
Population Health [Member]
Goodwill [Line Items]
Goodwill	431,132
Additions arising from business acquisitions	0
Total increases (decreases) due to measurement period adjustments:	28,571
Total additions to goodwill	28,571
Divestitures	(2,198)
Foreign exchange translation	0
Goodwill, net	457,505
Population Health [Member] \| Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Population Health [Member] \| Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Total increases (decreases) due to measurement period adjustments:	0
Population Health [Member] \| NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	117
Population Health [Member] \| EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	28,454
Netsmart [Member]
Goodwill [Line Items]
Goodwill	712,206
Additions arising from business acquisitions	1,374
Total increases (decreases) due to measurement period adjustments:	0
Total additions to goodwill	1,374
Divestitures	0
Foreign exchange translation	0
Goodwill, net	713,580
Netsmart [Member] \| Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Netsmart [Member] \| Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	1,374
Total increases (decreases) due to measurement period adjustments:	0
Netsmart [Member] \| NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	0
Netsmart [Member] \| EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	$ 0

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)		3 Months Ended
	Jan. 02, 2018	Mar. 31, 2018	Feb. 13, 2018	Feb. 06, 2018	Dec. 31, 2017
Schedule Of Goodwill And Intangible Assets [Line Items]
Accumulated impairment losses associated with goodwill		$ 0			$ 0
Additions		40,942,000
Total increases (decreases) due to measurement period adjustments:		37,570,000
Goodwill reduction due to divestiture		32,303,000
Goodwill, impairments recorded	$ 0
Goodwill		$ 2,051,437,000			$ 2,004,953,000
Hospital and Health Systems [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Percentage of excess of fair value over carrying value		10.00%
Goodwill		$ 511,200,000
EIS Business [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill reduction due to divestiture		2,200,000
One Content Business [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill reduction due to divestiture		30,100,000
Practice Fusion, Inc. [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions		34,739,000
Goodwill			$ 34,739,000
Cloud-based Analytics Software Platform Provider [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions		4,800,000
Goodwill				$ 4,800,000
Provider of Billing Solutions [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions		1,400,000
EIS Business [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Total increases (decreases) due to measurement period adjustments:		$ 37,658,000

Revenue from Contracts with Customers - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018 USD ($) Revenue_Stream
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams \| Revenue_Stream	2
Capitalized Contract Cost, Gross	$ 27.4
Capitalized Contract Cost Amortization	8.2
Total backlog	$ 4,700.0
Total backlog, percentage, year one	36.00%
Total backlog, percentage after year two	64.00%
Perpetual Software License Contracts [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Description of payment terms	The majority of our contracts contain provisions that require customer payment no later than one year from the transfer of control of the related performance obligation
Interest income recognized	$ 0.2
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	8.1
Cost of revenue [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	$ 0.1
Minimum [Member] \| Perpetual Software License Contracts [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Payments range	2 years
Maximum [Member] \| Perpetual Software License Contracts [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Payments range	10 years
ASC 606
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Deferred costs for fulfilment of contract	$ 8.6
ASC 606 \| Minimum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized cost, amortization period	2 years
ASC 606 \| Maximum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized cost, amortization period	9 years

Revenue from Contracts with Customers - Impact of Adoption on Previously Reported Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	$ 495,695		$ 567,873
Contract assets	45,068		0
Prepaid expenses and other current assets	130,051		115,463
Deferred revenue	540,289		546,830
Deferred revenue	25,876		24,047
Deferred taxes, net	117,061		93,643
Accumulated deficit	(319,271)		$ (338,150)
ASC 606
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net		$ 535,344
Contract assets		76,509
Prepaid expenses and other current assets		127,109
Deferred revenue		539,377
Deferred revenue		24,047
Deferred taxes, net		110,121
Accumulated deficit		(291,549)
ASC 606 \| Adjustments Due to ASC 606 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	78,302	(32,529)
Contract assets	(45,068)	76,509
Prepaid expenses and other current assets	33	11,646
Deferred revenue	(972)	(7,453)
Deferred revenue		0
Deferred taxes, net		16,478
Accumulated deficit	$ (4,618)	$ 46,601

Revenue from Contracts with Customers - Schedule of Comparison Between Reported Statements to Pro-forma Amounts in Effect of Previous Guidance - Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net	$ 495,695		$ 567,873
Contract assets	45,068		0
Prepaid expenses and other current assets	130,051		115,463
Contract assets - long-term	40,486		0
Deferred revenue	540,289		546,830
Deferred taxes, net	117,061
Accumulated deficit	(319,271)		$ (338,150)
ASC 606
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net		$ 535,344
Contract assets		76,509
Prepaid expenses and other current assets		127,109
Deferred revenue		539,377
Accumulated deficit		(291,549)
ASC 606 \| Adjustments Due to ASC 606 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net	78,302	(32,529)
Contract assets	(45,068)	76,509
Prepaid expenses and other current assets	33	11,646
Contract assets - long-term	(40,486)
Deferred revenue	(972)	(7,453)
Deferred taxes, net	(1,629)
Accumulated deficit	(4,618)	$ 46,601
Pro forma Under ASC 605 [Member] \| ASC 606
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net	573,997
Contract assets	0
Prepaid expenses and other current assets	130,084
Contract assets - long-term	0
Deferred revenue	539,317
Deferred taxes, net	115,432
Accumulated deficit	$ (323,889)

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation Of Revenue [Line Items]
Total revenue	$ 513,926	$ 413,475
Discontinued Operations [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(10,296)	0
Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(1,948)	858
Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	373,979	296,180
Population Health [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	69,705	43,430
Netsmart [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	82,486	73,007
Software delivery, Support and Maintenance [Member]
Disaggregation Of Revenue [Line Items]
Recurring revenue	294,455	227,450
Non-recurring revenue	35,311	40,738
Total revenue	329,766	268,188
Software delivery, Support and Maintenance [Member] \| Discontinued Operations [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(12,399)	0
Software delivery, Support and Maintenance [Member] \| Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,165	3,673
Software delivery, Support and Maintenance [Member] \| Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	230,557	178,330
Software delivery, Support and Maintenance [Member] \| Population Health [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	61,198	39,689
Software delivery, Support and Maintenance [Member] \| Netsmart [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	49,245	46,496
Client services [Member]
Disaggregation Of Revenue [Line Items]
Recurring revenue	122,474	101,779
Non-recurring revenue	61,686	43,508
Total revenue	184,160	145,287
Client services [Member] \| Discontinued Operations [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,103	0
Client services [Member] \| Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(3,113)	(2,815)
Client services [Member] \| Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	143,422	117,850
Client services [Member] \| Population Health [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	8,507	3,741
Client services [Member] \| Netsmart [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 33,241	$ 26,511

Interest Expense Related to 1.25% Notes (Detail) - 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 1,078	$ 1,078
Amortization of discounts and debt issuance costs	3,407	3,246
Total interest expense related to the 1.25% Notes	$ 4,485	$ 4,324

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended
Effective Tax Rates (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Loss from continuing operations before income taxes	$ (35,844)	$ (8,393)
Income tax benefit (provision)	$ 2,914	$ (172)
Effective tax rate	8.10%	(2.00%)

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 25,913	$ 47,714
Derivative liability, fair value	26,446	47,777
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract [Member] \| Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	503	1,136
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract [Member] \| Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] \| 1.25% Call Option [Member] \| Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	25,410	46,578
Not Designated as Hedging Instrument [Member] \| 1.25% Embedded Cash Conversion Option [Member] \| Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 26,446	$ 47,777

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018 USD ($) Derivative	Mar. 31, 2018 INR (₨) Derivative	Jun. 18, 2013 USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts \| Derivative	3	3
Derivative notional amount outstanding	$ 1,800,000	₨ 120,000,000
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income	$ 500,000
Estimated period of unrealized gains included in AOCI reclassified into income	12 months
Foreign Exchange Forward Contracts [Member] \| Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Apr. 30, 2018
Foreign Exchange Forward Contracts [Member] \| Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Jun. 30, 2018
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] \| Level 3 [Member] \| Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option			$ 82,800,000

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ (78)	$ 1,873
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	189	178
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	144	137
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 222	$ 210

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	$ 1,120,882
Other comprehensive income (loss) before reclassifications	65	$ (72,040)
Net losses (gains) reclassified from accumulated other comprehensive loss	(261)	(320)
Total other comprehensive loss	(196)	(72,360)
Balance at the end of the period	1,071,720
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(2,676)	(6,028)
Other comprehensive income (loss) before reclassifications	123	1,515
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0
Total other comprehensive loss	123	1,515
Balance at the end of the period	(2,553)	(4,513)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period		(56,420)
Other comprehensive income (loss) before reclassifications		(74,701)
Net losses (gains) reclassified from accumulated other comprehensive loss		0
Total other comprehensive loss		(74,701)
Balance at the end of the period		(131,121)
Derivatives Qualifying as Cash Flow Hedges [Member] \| Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	691	619
Other comprehensive income (loss) before reclassifications	(58)	1,146
Net losses (gains) reclassified from accumulated other comprehensive loss	(261)	(320)
Total other comprehensive loss	(319)	826
Balance at the end of the period	372	1,445
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(1,985)	(61,829)
Balance at the end of the period	$ (2,181)	$ (134,189)

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)			$ 60	$ 61
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 131	$ 445	$ 924	$ 402